Atlas Trials

Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer

Clinical trial NCT04498793 · UNKNOWN

Trial details

NCT number
NCT04498793
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
HER2-negative Breast Cancer
Start date
2020-09-01
Primary completion
2021-12-01
Enrollment
55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.